{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:44:14Z","timestamp":1782902654392,"version":"3.54.5"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"publisher","award":["RUZZ_BIRD23_01"],"award-info":[{"award-number":["RUZZ_BIRD23_01"]}],"id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"publisher","award":["BIRD2222_01"],"award-info":[{"award-number":["BIRD2222_01"]}],"id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"publisher","award":["BIRD2121_01"],"award-info":[{"award-number":["BIRD2121_01"]}],"id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ijbiomac.2024.138305","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T03:13:27Z","timestamp":1733195607000},"page":"138305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Critical role of protein kinase CK2 in chronic myeloid leukemia cells harboring the T315I BCR::ABL1 mutation"],"prefix":"10.1016","volume":"286","author":[{"given":"Camila Paz","family":"Quezada Meza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Salizzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Calistri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Zavatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Marmiroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing Z.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Donella-Deana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Borgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ruzzene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2024.138305_bb0005","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc2368","article-title":"Getting to the stem of chronic myeloid leukaemia","volume":"8","author":"Savona","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3390\/pharmaceutics14010215","article-title":"BCR-ABL1 tyrosine kinase complex signaling transduction: challenges to overcome resistance in chronic myeloid leukemia","volume":"14","author":"Amarante-Mendes","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0015","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.3390\/cancers13102311","article-title":"Current views on the interplay between tyrosine kinases and phosphatases in chronic myeloid leukemia","volume":"13","author":"Boni","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0020","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2217\/14796694.2.6.655","article-title":"Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib","volume":"2","author":"Quint\u00e1s-Cardama","year":"2006","journal-title":"Future Oncol."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0025","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance","volume":"145","author":"Kantarjian","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic myeloid leukemia: modern therapies, current challenges and future directions","volume":"49","author":"Osman","year":"2021","journal-title":"Blood Rev."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0035","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/PPO.0b013e31823dec8d","article-title":"Evolution of therapies for chronic myelogenous leukemia","volume":"17","author":"Santos","year":"2011","journal-title":"Cancer J. Sudbury Mass"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0040","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.3390\/cancers13194820","article-title":"Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance","volume":"13","author":"Alves","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0045","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/asheducation-2009.1.461","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance","author":"Bixby","year":"2009","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0050","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0055","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.leukres.2007.11.008","article-title":"Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines","volume":"32","author":"Deguchi","year":"2008","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0060","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s12185-021-03127-5","article-title":"Current status and novel strategy of CML","volume":"113","author":"Morita","year":"2021","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0065","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0070","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/asheducation-2005.1.183","article-title":"Loss of response to imatinib: mechanisms and management","volume":"2005","author":"Shah","year":"2005","journal-title":"Hematology"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0075","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/14656566.2022.2064742","article-title":"Ponatinib for the treatment of adult patients with resistant or intolerant chronic-phase chronic myeloid leukemia","volume":"23","author":"Haddad","year":"2022","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0080","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/ajh.26686","article-title":"Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia","volume":"97","author":"Kantarjian","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0085","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000505486","article-title":"Cardiovascular toxicity in cancer patients treated with tyrosine kinase inhibitors: a real-world single-center experience","volume":"98","author":"Novo","year":"2020","journal-title":"Oncology"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0090","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0095","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/bloodadvances.2019001329","article-title":"First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis","volume":"4","author":"Vener","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0100","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0105","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0110","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41375-024-02159-0","article-title":"Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials","volume":"38","author":"Jabbour","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0115","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/s41375-024-02278-8","article-title":"Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after \u22651 prior tyrosine kinase inhibitor: 2-year follow-up results","volume":"38","author":"Cortes","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0120","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-022-01334-z","article-title":"Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial, J. Hematol. Oncol","volume":"15","author":"Jiang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0125","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.3390\/cancers15164161","article-title":"A multicenter retrospective chart review study of treatment and disease patterns and clinical outcomes of patients with chronic-phase chronic myeloid leukemia in third-line treatment or with T315I mutation","volume":"15","author":"Nicolini","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0130","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/10409238.2021.1908951","article-title":"How can a traffic light properly work if it is always green? The paradox of CK2 signaling","volume":"56","author":"Borgo","year":"2021","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0135","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41392-021-00567-7","article-title":"Protein kinase CK2: a potential therapeutic target for diverse human diseases","volume":"6","author":"Borgo","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0140","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.bbapap.2007.08.017","article-title":"Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2","volume":"1784","author":"Duncan","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0145","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1007\/s00018-009-9154-y","article-title":"Protein kinase CK2 in health and disease: CK2: a key player in cancer biology","volume":"66","author":"Trembley","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0150","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.molonc.2013.08.006","article-title":"Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives","volume":"7","author":"Borgo","year":"2013","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0155","doi-asserted-by":"crossref","first-page":"18204","DOI":"10.18632\/oncotarget.7569","article-title":"Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies","volume":"7","author":"Salizzato","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0160","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1021\/jm101251q","article-title":"Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer","volume":"54","author":"Pierre","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0165","doi-asserted-by":"crossref","first-page":"8478","DOI":"10.1021\/bi2008382","article-title":"Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer","volume":"50","author":"Battistutta","year":"2011","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0284876","article-title":"Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells","volume":"18","author":"Mitrovsk\u00fd","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049193","article-title":"Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells","volume":"7","author":"Zanin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0180","first-page":"3603","article-title":"Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase","volume":"53","author":"Beran","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0185","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1182\/blood-2004-12-4704","article-title":"Regulation of survivin expression through Bcr-Abl\/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells","volume":"107","author":"Carter","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0190","doi-asserted-by":"crossref","DOI":"10.1038\/srep42409","article-title":"Generation and quantitative proteomics analysis of CK2\u03b1\/\u03b1\u2032(\u2212\/\u2212) cells","volume":"7","author":"Borgo","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0195","article-title":"CRISPR multitargeter: a web tool to find common and unique CRISPR single guide RNA targets in a set of similar sequences","volume":"10","author":"Prykhozhij","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0200","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1093\/bioinformatics\/btu354","article-title":"GT-Scan: identifying unique genomic targets","volume":"30","author":"O\u2019Brien","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0205","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.abb.2014.01.006","article-title":"CK2 involvement in ESCRT-III complex phosphorylation","volume":"545","author":"Salvi","year":"2014","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0210","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0215","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0220","first-page":"5995","article-title":"Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR\/ABL-positive cell line","volume":"62","author":"Ricci","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0225","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1007\/s00018-009-0108-1","article-title":"Dephosphorylation and inactivation of Akt\/PKB is counteracted by protein kinase CK2 in HEK 293T cells","volume":"66","author":"Di Maira","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0230","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/sj.cdd.4401604","article-title":"Protein kinase CK2 phosphorylates and upregulates Akt\/PKB","volume":"12","author":"Di Maira","year":"2005","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0235","doi-asserted-by":"crossref","first-page":"32592","DOI":"10.1074\/jbc.M001358200","article-title":"Tumor necrosis factor alpha-induced phosphorylation of RelA\/p65 on Ser529 is controlled by casein kinase II","volume":"275","author":"Wang","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0240","doi-asserted-by":"crossref","first-page":"10288","DOI":"10.1158\/0008-5472.CAN-10-1893","article-title":"CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy","volume":"70","author":"Siddiqui-Jain","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0245","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=CX-4945&cntry=&state=&city=&dist=, (n.d.)."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0250","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0117-x","article-title":"Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer","volume":"32","author":"Wingelhofer","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0255","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0260","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood.2019001645","article-title":"Specific stimulation of T lymphocytes with erythropoietin for adoptive immunotherapy","volume":"135","author":"Vinanica","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0265","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/15384101.2015.1006970","article-title":"BCR-ABL inactivates cytosolic PTEN through casein kinase II mediated tail phosphorylation","volume":"14","author":"Morotti","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0270","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1432-1033.1994.tb18651.x","article-title":"Biosynthesis of casein kinase II in lymphoid cell lines","volume":"220","author":"L\u00fcscher","year":"1994","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0275","doi-asserted-by":"crossref","first-page":"42409","DOI":"10.1038\/srep42409","article-title":"Generation and quantitative proteomics analysis of CK2\u03b1\/\u03b1\u2032(\u2212\/\u2212) cells","volume":"7","author":"Borgo","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0280","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aau9060","article-title":"Cell-based screen identifies a new potent and highly selective CK2 inhibitor for modulation of circadian rhythms and cancer cell growth","volume":"5","author":"Oshima","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2020.12.013","article-title":"Development of a potent and selective chemical probe for the pleiotropic kinase CK2","author":"Wells","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0290","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0295","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","article-title":"European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia","volume":"37","author":"Cross","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0300","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3324\/haematol.2017.171249","article-title":"Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I\/II study","volume":"103","author":"Gambacorti-Passerini","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108221","article-title":"TGF\u03b2R-SMAD3 signaling induces resistance to PARP inhibitors in the bone marrow microenvironment","volume":"33","author":"Le","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0310","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jcp.21908","article-title":"The hematopoietic stem cell niche: low in oxygen but a nice place to be","volume":"222","author":"Eliasson","year":"2010","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0315","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1042\/bj3570563","article-title":"Autocatalytic tyrosine-phosphorylation of protein kinase CK2 alpha and alpha' subunits: implication of Tyr182","volume":"357","author":"Donella-Deana","year":"2001","journal-title":"Biochem. J."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0320","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1042\/bj20021905","article-title":"Tyrosine phosphorylation of protein kinase CK2 by Src-related tyrosine kinases correlates with increased catalytic activity","volume":"372","author":"Donella-Deana","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0325","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1038\/sj.onc.1210495","article-title":"Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level","volume":"26","author":"Di Maira","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0330","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1021\/pr070500s","article-title":"Mass spectrometry analysis of a protein kinase CK2beta subunit interactome isolated from mouse brain by affinity chromatography","volume":"7","author":"Arrigoni","year":"2008","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0335","series-title":"Adv. Protein Chem. Struct. Biol","article-title":"Protein kinase CK2 inhibition as a pharmacological strategy","author":"Borgo","year":"2021"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2021.02.002","article-title":"A new chemical probe challenges the broad cancer essentiality of CK2","author":"Licciardello","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0345","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41420-021-00717-4","article-title":"Targeting CK2 in cancer: a valuable strategy or a waste of time?","volume":"7","author":"Salvi","year":"2021","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0350","doi-asserted-by":"crossref","first-page":"57","DOI":"10.18632\/oncoscience.9","article-title":"Modeling the influence of stromal microenvironment in the selection of ENU-induced BCR-ABL1 mutants by tyrosine kinase inhibitors","volume":"1","author":"Aggoune","year":"2014","journal-title":"Oncoscience"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0355","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/life13020259","article-title":"IGFBP-6 alters mesenchymal stromal cell phenotype driving dasatinib resistance in chronic myeloid leukemia","volume":"13","author":"Cambria","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.ijbiomac.2024.138305_bb0360","doi-asserted-by":"crossref","first-page":"248","DOI":"10.20892\/j.issn.2095-3941.2016.0023","article-title":"Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang","volume":"13","author":"Zhou","year":"2016","journal-title":"Cancer Biol. Med."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813024091165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813024091165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T09:51:06Z","timestamp":1782899466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813024091165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":72,"alternative-id":["S0141813024091165"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.138305","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Critical role of protein kinase CK2 in chronic myeloid leukemia cells harboring the T315I BCR::ABL1 mutation","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.138305","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"138305"}}